Clinical Trials | A Phase II Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed or Refractory CD10-Negative Diffuse-Large B-Cell Lymphoma (DLBCL) and High-Grade B-Cell Lymphoma with MYC and BCL2 rearrangements (HGBCL-DH-BCL2)

The University of Virginia is conducting a clinical research study for adults 18 and over who have relapsed and/or refractory aggressive B-cell lymphoma. The purpose of this study is to test the good and bad effects of the combination targeted therapy medications of venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide (ViPOR). ViPOR could shrink your cancer. The ViPOR medications venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide, are already approved by the FDA for use in lymphoma individually but are currently not approved by the FDA for treatment of lymphoma in combination. In this study, you will get the usual medication called prednisone. You also will get the study medications venetoclax, ibrutinib, obinutuzumab, and lenalidomide. You will take venetoclax as a pill by mouth on days 2 through 14. You will take ibrutinib as a pill by mouth on days 1 through 14. You will take prednisone as a pill by mouth on days 1 through 7. You will take lenalidomide as a pill by mouth on days 1 through 14. You will get obinutuzumab through a vein in your arm on the first and second day of each cycle. Each cycle lasts 21 days. You will receive study treatment for approximately 6 months. After study treatment, you will be followed for up to 10 years. Study-related procedures that are being done beyond your standard of care will be provided at no cost to you or your insurance. Additional information can be found here: https://clinicaltrials.gov/study/NCT06649812 [email protected]